ECSS
VKTX icon

Eurizon Capital SGR SpA’s Viking Therapeutics VKTX Stock Holding History

Eurizon Capital SGR SpA’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.8K Hold
1,512
– – ﹤0.01% 999
2026
Q1 		$45.5K Buy
+1,512
New +$48.6K ﹤0.01% 1035

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Eurizon Capital SGR SpA's VKTX Position: Q2 2026 in Review

Eurizon Capital SGR SpA held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 1,512 shares worth $59.8K. The position accounts for ﹤0.01% of the portfolio, ranked #999.

Eurizon Capital SGR SpA first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Eurizon Capital SGR SpA held 1,512 shares of Viking Therapeutics worth $59.8K as of Q2 2026.
  • Eurizon Capital SGR SpA left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #999 holding.
  • Eurizon Capital SGR SpA first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.